Taking people in FranceNo phase

Studies how body weight and blood sugar affect gene activity in tissues

Collects tissue samples from adults with obesity or blood sugar problems to study gene activity.

Key facts

Who runs it: University Hospital, Lille
Where: Lille, FranceSee the site
Trial code: NCT01129297
Registry title: A Biological Atlas of Severe Obesity (Biological Tissue Collection)
Status: Recruiting
People taking part: 20,000 people, planned
Started: 13 Jun 2006
Expected to end: Jun 2027
Type of study: Observational, 5 groups
Record updated: 8 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 who need abdominal surgery and have a certain body weight and blood sugar status. Tissue samples are collected during surgery.

Age: 18 to 65 years
Sex: All sexes can join.
Disease stage: Body Mass Index (BMI) and blood sugar status must fit one of the listed groups. Severe obesity (BMI ≥ 35 kg/m2) with diabetes, with glucose intolerance, or without diabetes. Or BMI < 27 kg/m2 without diabetes. Or BMI between 27 and 35 kg/m2 without diabetes.
Biomarker or test result: Fasting blood glucose and blood glucose 120 minutes after drinking glucose must fit the group. Diabetes: fasting ≥ 7 mmol/l and/or ≥ 11.1 mmol/l at 120 minutes. Glucose intolerance: fasting > 6 and < 7 mmol/l and/or > 7.8 and < 11.1 mmol/l at 120 minutes. No diabetes: ≤ 6 mmol/L and/or ≤ 7.8 mmol/l at 120 minutes.

Main reasons for not taking part

Cannot receive clear information about the trial
Refuses to sign the consent form
Has another condition that the surgeon judges may raise the risk of problems from tissue sampling

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

Age between 18 and 65 years
Indication of abdominal surgery requiring a laparotomy or laparoscopy for bariatric surgery, cholecystectomy, or parietal surgical
Phenotype corresponding to one of the following four cases :; Body Mass Index ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route); Body Mass Index ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose> 6 mmol/L and <7 mmol/l and/or> 7.8 mmol/l and <11.1 mmol/l , 120 minutes after ingestion of glucose (hyperglycemia caused by oral route); Body Mass Index ≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route); Body Mass Index <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route); 5)27 <Body Mass Index <35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)

Who cannot take part

unable to receive clear information
refusal to sign the consent form
pathology associated judged by the surgeon, may increase the risk of adverse events related to sampling tissue

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 18 and 65 years old?

Where in France

Lille University HospitalLille, FranceContact: François PATTOU, MD, PhDTaking people

About the trial

What the trial wants to find out

Type 2 diabetes and obesity are both multifactorial diseases resulting from gene-environment interactions. However, this interaction, as well as the specific effect of each polymorphism, remains poorly understood.

Read full original descriptionShow less

We now proposed a prospective cohort study to improve our understanding of the influence of phenotypic characteristics on gene expression in tissues involved in glucose and/or lipid metabolism by collecting different biological samples.

The 5 groups in the trial

BMI ≥ 35 kg/m2 and diabetes
BMI (Body Mass Index) ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
BMI ≥ 35 kg/m2 with intolerance glucose
BMI (Body Mass Index) ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose\> 6 mmol/L and \<7 mmol/l and / or\> 7.8 mmol/l and \<11.1 mmol/l , 120 minutes after ingestion of glucose (oral glucose tolerance test)
BMI ≥ 35 kg/m2 without diabetes
BMI (Body Mass Index)≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
BMI <27 kg/m2 without diabetes
BMI (Body Mass Index) \<27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
27 < BMI < 35 kg/m2 without diabetes
BMI (Body Mass Index) \<27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)